COVID-19

© GettyImages/ipopba

Study: Early test and treat is vital in people infected with COVID-19

By Jane Byrne

A new mathematical modeling study by Ashish Goyal and colleagues, informed by data collected from 25 patients hospitalized with COVID-19 in four different countries, offers some important new insights into the optimal timing of four different antiviral...

© GettyImages/YurolaitsAlbert

Lilly's COVID-19 antibody trial on hold over safety concerns

By Jane Byrne

Enrollment is temporarily on hold in the ACTIV-3 clinical trial, which is evaluating Lilly's investigational neutralizing antibody bamlanivimab (LY-CoV555) as a treatment for COVID-19 in hospitalized patients. The pause was recommended by the study's...

Pic:getty/daniilantiq

Industry welcomes release of FDA COVID-19 vaccine guidance

By Rachel Arthur

On Tuesday the FDA released its guidance on Emergency Use Authorization for COVID-19 vaccines: a move welcomed by the industry as a ‘tried and true tradition of releasing guidance in a public and transparent way’.

© GettyImages/metamorworks

Fujifilm expands its gene therapy drug CDMO business

By Jane Byrne

Fujifilm is boosting its gene therapy offering, taking the first steps to expand its viral vector contract development and manufacturing organization (CDMO) services to Europe, at the site of Fujifilm Diosynth Biotechnologies (FDB) in the North East of...

© GettyImages/solarseven

Cobra to supply plasmids to UK COVID-19 vaccine developer

By Jane Byrne

Contract development and manufacturing organization (CDMO), Cobra Biologics, has been selected to manufacture plasmids for a Phase I clinical trial of a COVID-19 vaccine being developed by UK company, Scancell.

© GettyImages/AndreyPopov

Crowdfunding COVID-19 vaccine development

By Jane Byrne

Axon Neuroscience is launching the world's first crowdfunding exercise for the development of a COVID-19 vaccine, following what it says are strong pre-clinical results for its candidate.

Pic:getty/licsiren

Johnson & Johnson starts Phase 3 trial for COVID-19 vaccine

By Rachel Arthur

Johnson & Johnson has launched its pivotal global Phase 3 trial for its COVID-19 vaccine candidate: anticipating the first batches of its vaccine will be available for emergency use authorization in early 2021.

A broad shift in the gene therapy space impacts demand for viral vectors. Pic: getty/yourphoto

Why viral vector manufacturing capacity is constrained

By Nick Taylor

Viral vector production capacity has become increasingly constrained in recent years due to increases in the therapies in development, the dosages given and the patient populations targeted. COVID-19 is exacerbating the situation.

© GettyImages/ipopba

Cytiva invests for global capacity expansion

By Jane Byrne

Cytiva is to invest US$500m over the next five years to raise manufacturing capacity, hiring nearly 1,000 personnel in Austria, China, Singapore, Sweden, and the US, and bringing on new manufacturing lines, 24/7 shift patterns, and increased automation.

© GettyImages/vchal

Spotlight on Moderna funding declarations in patent filings

By Jane Byrne

Two US government agencies are investigating whether Moderna Therapeutics, the biotech company behind one of the leading Covid-19 vaccine candidates, was upfront about government funding in its filed or awarded patents, as required by federal law.

Follow us

Products

View more

Webinars